Health Diagnostic Laboratory Inc. (HDL, Inc.) has brought Dr. Joseph McConnell to Richmond, Virginia as the Chief Medical Officer and co-founder of the growing clinical laboratory focused on fighting the alarming increase in chronic disease.
"Dr. McConnell is a distinguished medical professional and formerly the Director of Cardiovascular Laboratory Medicine in the Department of Laboratory Medicine at Mayo Clinic. He currently drives our laboratory forward with an unwavering commitment to empowering both physicians and patients," said Tonya Mallory, President and CEO of HDL, Inc., an accredited clinical laboratory that has emerged as a leader in disease state management.
Dr. McConnell is formally the Chair of the Clinical Chemistry Fellowship Program and the Medical Director of the Clinical Laboratory Sciences Program at the Mayo Clinic. He held a joint appointment in the Cardiovascular Diseases Section of the Division of Internal Medicine at the Mayo Clinic. Dr. McConnell’s primary research interest is in the field of atherosclerosis, specifically the use of novel risk factors to identify subjects at increased risk for developing cardiovascular disease and events with a focus on prevention. "Dr. McConnell has co-authored over 80 manuscripts in peer-reviewed, scientific literature on topics in cardiovascular disease and risk management. He is the very definition of a medical leader," said Mallory.
Health Diagnostic Laboratory, Inc., located at the Virginia Biotechnology Research Park, is changing the way clinical laboratories interact with physicians and patients. The professionals at HDL, Inc., such as Dr. McConnell, partner with clients to provide the most advanced practices for diagnosis and treatment of cardiovascular and related chronic diseases. The award-winning laboratory offers a comprehensive panel of tests to help physicians personalize treatment based on more complete patient profiling. The result — earlier detection of risk factors pre-disposing patients to disease, more advanced evidence-based treatments, and fewer patients progressing to overt disease.
Source: HDL, Inc.
